share_log
Benzinga ·  May 2 07:38
FDA Clears Palatin's IND Application For Phase 2 Study Of Bremelanotide Co-Administered With Tirzepatide For Obesity, The Phase 2 Study Is Expected To Start By Mid-2024, With Topline Data Results By The End Of 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment